Natalizumab

Reduce direct handling to a minimum and wear appropriate protective clothing		
CAUTION: High Administration Risk Rating		
Form & Storage	Concentrate for solution for infusion	Refrigerate unopened vials at 2°C - 8°C and protect from light.
Reconstitution	Already in Solution	
Compatibility & Stability	Sodium Chloride 0.9%	
Administration	Natalizumab solutions should be inspected visually prior to dilution and administration, and should be discarded if there are visible particles and/or discoloration. The liquid should be clear to slightly opalescent. **IV Infusion** • Add the contents of the vial (15mL) to 100mL bag of sodium chloride 0.9%, Invert gently to mix completely and to avoid foaming. Do not shake. • The total volume to be administered is 115ml. Administer over approximately 1 hour at a rate of approximately 2mL per minute. See **PPG-CUH-CUH-243** Policy Procedure and Guidelines for Management of Patients Attending CUH Infusion Unit for Intravenous Therapy CUH for more information	
Documentation Requirements	Document batch numbers and expiry dates of vials in medical notes.	
Adverse Drug Reactions	Medicinal products for the treatment of hypersensitivity reactions, e.g. adrenaline, oxygen, antihistamines and corticosteroids should be available for immediate use in the event of an allergic reaction during administration of all infusions.	
Disposal	Dispose of infusion bag and administration set in purple-lidded bin.	

Information provided relates to Tysabri manufactured by Biogen